Cargando…

Trends of rapamycin in survival benefits of liver transplantation for hepatocellular carcinoma

The proportion of liver transplantation (LT) for hepatocellular carcinoma (HCC) has kept on increasing over the past years and account for 20%-40% of all LT. Post-transplant HCC recurrence is considered the most important factor affecting the long-term survival of patients. The use of different type...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Yang, Liu, Yu, Zhou, Lin, Du, Guo-Sheng, He, Qiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8462078/
https://www.ncbi.nlm.nih.gov/pubmed/34621472
http://dx.doi.org/10.4240/wjgs.v13.i9.953
_version_ 1784572123395653632
author Zhao, Yang
Liu, Yu
Zhou, Lin
Du, Guo-Sheng
He, Qiang
author_facet Zhao, Yang
Liu, Yu
Zhou, Lin
Du, Guo-Sheng
He, Qiang
author_sort Zhao, Yang
collection PubMed
description The proportion of liver transplantation (LT) for hepatocellular carcinoma (HCC) has kept on increasing over the past years and account for 20%-40% of all LT. Post-transplant HCC recurrence is considered the most important factor affecting the long-term survival of patients. The use of different types of immunosuppressive agents after LT is closely associated with an increased risk for HCC recurrence. The most commonly used conventional immunosuppressive drugs include the calcineurin inhibitors tacrolimus (FK506) and mammalian target of rapamycin inhibitor rapamycin (RAPA). Compared with tacrolimus, RAPA may carry an advantage in survival benefit because of its anti-tumor effects. However, no sufficient evidence to date has proven that RAPA could increase long-term recurrence-free survival and its anti-tumor mechanism of combined therapy remains incompletely clear. In this review, we will focus on recent advances in clinical application experience and basic research results of RAPA in patients undergoing LT for HCC to further guide the clinical practice.
format Online
Article
Text
id pubmed-8462078
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-84620782021-10-06 Trends of rapamycin in survival benefits of liver transplantation for hepatocellular carcinoma Zhao, Yang Liu, Yu Zhou, Lin Du, Guo-Sheng He, Qiang World J Gastrointest Surg Minireviews The proportion of liver transplantation (LT) for hepatocellular carcinoma (HCC) has kept on increasing over the past years and account for 20%-40% of all LT. Post-transplant HCC recurrence is considered the most important factor affecting the long-term survival of patients. The use of different types of immunosuppressive agents after LT is closely associated with an increased risk for HCC recurrence. The most commonly used conventional immunosuppressive drugs include the calcineurin inhibitors tacrolimus (FK506) and mammalian target of rapamycin inhibitor rapamycin (RAPA). Compared with tacrolimus, RAPA may carry an advantage in survival benefit because of its anti-tumor effects. However, no sufficient evidence to date has proven that RAPA could increase long-term recurrence-free survival and its anti-tumor mechanism of combined therapy remains incompletely clear. In this review, we will focus on recent advances in clinical application experience and basic research results of RAPA in patients undergoing LT for HCC to further guide the clinical practice. Baishideng Publishing Group Inc 2021-09-27 2021-09-27 /pmc/articles/PMC8462078/ /pubmed/34621472 http://dx.doi.org/10.4240/wjgs.v13.i9.953 Text en ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
spellingShingle Minireviews
Zhao, Yang
Liu, Yu
Zhou, Lin
Du, Guo-Sheng
He, Qiang
Trends of rapamycin in survival benefits of liver transplantation for hepatocellular carcinoma
title Trends of rapamycin in survival benefits of liver transplantation for hepatocellular carcinoma
title_full Trends of rapamycin in survival benefits of liver transplantation for hepatocellular carcinoma
title_fullStr Trends of rapamycin in survival benefits of liver transplantation for hepatocellular carcinoma
title_full_unstemmed Trends of rapamycin in survival benefits of liver transplantation for hepatocellular carcinoma
title_short Trends of rapamycin in survival benefits of liver transplantation for hepatocellular carcinoma
title_sort trends of rapamycin in survival benefits of liver transplantation for hepatocellular carcinoma
topic Minireviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8462078/
https://www.ncbi.nlm.nih.gov/pubmed/34621472
http://dx.doi.org/10.4240/wjgs.v13.i9.953
work_keys_str_mv AT zhaoyang trendsofrapamycininsurvivalbenefitsoflivertransplantationforhepatocellularcarcinoma
AT liuyu trendsofrapamycininsurvivalbenefitsoflivertransplantationforhepatocellularcarcinoma
AT zhoulin trendsofrapamycininsurvivalbenefitsoflivertransplantationforhepatocellularcarcinoma
AT duguosheng trendsofrapamycininsurvivalbenefitsoflivertransplantationforhepatocellularcarcinoma
AT heqiang trendsofrapamycininsurvivalbenefitsoflivertransplantationforhepatocellularcarcinoma